Christopher Wallis, MD, PhD, FRCSC, University of Toronto, highlights his population-based research on treatment intensification shortcomings in de novo mCSPC, including why guideline-concordant care is lagging, barriers to such care, and some of the patient, physician, and system characteristics that contribute to variation in treatment intensification.
Treatment Intensification Variation for De Novo mCSPC: A Population-Based Cohort Study
By Christopher Wallis, MD, PhD, FRCSC - Last Updated: January 30, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.